Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older
• People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer), confirmed through laboratory testing of tissue or cell samples
• People whose cancer has tested negative for a marker called microsatellite instability (described as "microsatellite stable" or MSS)
• People who have at least one area of cancer that can be measured using standard imaging guidelines
• People whose cancer has continued to grow or spread after at least one previous cancer treatment
• People who are not currently receiving certain other treatments, including immune therapies, chemotherapy, immunosuppressive drugs, or other experimental treatments
• People who do not have a known HIV infection or an active Hepatitis B infection
• People who are considered reasonably well and active in daily life, as measured by a standard medical scale (ECOG score of 0 or 1) (confirm with trial site)
• People with a life expectancy of at least 3 months
• People whose recent blood test results (taken within 4 weeks before starting treatment) meet specific minimum levels for blood cells, kidney function, liver function, and blood clotting (confirm with trial site for exact values)
• People who have at least one area of cancer that has not previously been treated with radiation and can be safely biopsied before treatment begins
• People whose cancer has spread to the liver but where the liver tumour involvement makes up no more than 25% of the total liver size
• Women who could become pregnant must have a negative pregnancy test within 7 days before starting treatment
• All participants who are able to have children must agree to use effective contraception or abstain from sexual activity during the study and for at least 6 months after the last dose of the study drugs

Who may not be able to join:

• People whose liver tumours make up more than 25% of the total liver volume
• People who have cancer that has spread to the brain or spinal cord and is currently untreated or active
• People who have an active autoimmune disease, or who have had an autoimmune disease that required systemic medication within the past 2 years
• People who need regular treatment with corticosteroids at doses above a low threshold, or who have taken other immunosuppressive medications within 30 days before joining the trial (low-dose steroids and inhaled or topical steroids may be permitted in some cases — confirm with trial site)
• People who have previously had radiation therapy directed at the liver, or any procedure to block blood flow to the liver
• People who have needed a procedure to drain abdominal fluid in the past 4 weeks, or who have a history of serious liver failure, including episodes of brain confusion caused by liver problems or abnormal ammonia levels in the blood
• People who have had a full or partial bowel blockage in the past 3 months, or who currently show signs of a bowel blockage
• People with serious or active heart or blood vessel conditions, including stroke or heart attack within the past 6 months, unstable chest pain, significant heart failure, or uncontrolled heart rhythm problems
• People with an abnormal heart rhythm measurement (QTcF greater than 480 ms) on an ECG (confirm with trial site)
• People who have previously received an organ transplant from another person
• People who have had chemotherapy or targeted cancer therapy within 2 weeks before starting this trial
• People who are still experiencing significant side effects (grade 2 or higher) from previous cancer treatments, with the exception of nerve-related side effects
• People who have another cancer that currently requires active treatment
• People who have a history of lung inflammation not caused by infection
• People who have an active infection that currently requires antibiotic treatment
• People who have received a live vaccine within 30 days before starting the trial
• People who have received a COVID-19 vaccine or booster within 7 days before the first treatment date
• People who have had a severe allergic reaction to a type of drug called a monoclonal antibody
• People who are not able to make decisions for themselves regarding participation

Important: Always verify eligibility with the trial site directly before applying.